Search Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupComplicationsDiseaseOsteoporosisSubgroupICD10M80.-M80.0-M80.4-M81.-M81.0-M81.4-MeSHOsteoporosisSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceDenosumabSupportive substanceDenosumabSupportive substanceDenosumabSupportive substanceDenosumabNo. Substances1Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseTherapy intentionsupportiveRisksCardiotoxicityDiarrheaEdemaHypertensionInfectionsOsteonecrosis of the JawPneumoniaRash only studiesPublicationAuthorSmith M / Cummings S / Saag KDiseaseFrauen postmenopausal mit Frakturen / Männer unter Androgendeprivationstherpaie / Glucokorticoidinduzierte Osteoporose, ECOG 0-2OriginDenosumab HALT Prostate Cancer Study Group / FREEDOM Trial / University of Alabama, Birmingham, USAProtocols in Revision 1 protocol foundProtocols under revision.Denosumab 60, Osteoporosis (PID1383 V1.0)
